The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $443,220 Project Grant to the Beckman Research Institute of the City of Hope. The goal of this 5-year project is to further understand the role, mechanism, and therapeutic potential of the RNA methyltransferase METTL1 in acute myeloid leukemia (AML). The research aims to: 1) consolidate the importance of METTL1 function in AML using mouse models; 2) delineate the molecular mechanism through which the METTL1/m7G axis facilitates leukemia stem cell homeostasis; and 3) evaluate the therapeutic potential of pharmacologically targeting METTL1 to treat AML. The project leverages the expertise of the Beckman Research Institute, a nonprofit medical research organization, to advance the understanding of how dysregulation of RNA modifications contributes to AML and explore METTL1 as a potential therapeutic target.
Generated 3/4/25, 7:24 AM